Literature DB >> 15892150

Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis.

Chih-Ken Chen1, Shih-Ku Lin, Pak C Sham, David Ball, El-Wui Loh, Robin M Murray.   

Abstract

It is not clear why some methamphetamine (MAMP) abusers develop psychotic symptoms, while others use MAMP regularly over long periods and remain unscathed. We tested the hypotheses that those users who develop MAMP-induced psychosis (MIP) have greater familial loading for psychotic disorders than users with no psychosis. Four hundred forty-five MAMP users were recruited from a psychiatric hospital and a detention center in Taipei, and were assessed with the Diagnostic Interview for genetic studies (DIGS-C) and the Family Interview for genetic study (FIGS-C). Morbid risk (MR) for psychiatric disorders in first-degree relatives was compared between those MAMP users with a lifetime diagnosis of MAMP psychosis and those without. The relatives of MAMP users with a lifetime diagnosis of MAMP psychosis had a significantly higher MR for schizophrenia (OR = 5.4, 95% CI: 2.0-14.7, P < 0.001) than the relatives of those probands who never became psychotic. Furthermore, the MR for schizophrenia in the relatives of the subjects with a prolonged MAMP psychosis (MIP-P) was higher than in the relatives of those users with a brief MAMP psychosis (MIP-B) (OR = 2.8, 95% CI: 1.0-8.0, P = 0.042). The greater his or her familial loading for schizophrenia, the more likely a MAMP user is to develop psychosis, and the longer that psychosis is likely to last. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15892150     DOI: 10.1002/ajmg.b.30187

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  36 in total

Review 1.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

Review 2.  Neurologic manifestations of chronic methamphetamine abuse.

Authors:  Daniel E Rusyniak
Journal:  Neurol Clin       Date:  2011-06-24       Impact factor: 3.806

3.  Capacity building and collaborative research on cross-national studies in the Asian region.

Authors:  Yih-Ing Hser; Linda Chang; Gene-Jack Wang; Ming D Li; Richard Rawson; Steve Shoptaw; Jacques Normand; Betty Tai
Journal:  J Food Drug Anal       Date:  2013-12-01       Impact factor: 6.079

4.  Clinical features of methamphetamine-induced paranoia and preliminary genetic association with DBH-1021C→T in a Thai treatment cohort.

Authors:  Rasmon Kalayasiri; Viroj Verachai; Joel Gelernter; Apiwat Mutirangura; Robert T Malison
Journal:  Addiction       Date:  2014-03-17       Impact factor: 6.526

5.  Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample.

Authors:  Kenneth S Kendler; Henrik Ohlsson; Jan Sundquist; Kristina Sundquist
Journal:  Am J Psychiatry       Date:  2019-05-06       Impact factor: 18.112

6.  N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.

Authors:  Twanette Swanepoel; Marisa Möller; Brian Herbert Harvey
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

7.  Prenatal genetic counselling for psychiatric disorders.

Authors:  Angela Inglis; Emily Morris; Jehannine Austin
Journal:  Prenat Diagn       Date:  2016-08-23       Impact factor: 3.050

8.  Prevalence and clinical characteristics of psychotic versus nonpsychotic major depression in a general psychiatric outpatient clinic.

Authors:  Brandon A Gaudiano; Kristy L Dalrymple; Mark Zimmerman
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

9.  Evidence for shared genetic risk between methamphetamine-induced psychosis and schizophrenia.

Authors:  Masashi Ikeda; Yuko Okahisa; Branko Aleksic; Mujun Won; Naoki Kondo; Nobuya Naruse; Kumi Aoyama-Uehara; Ichiro Sora; Masaomi Iyo; Ryota Hashimoto; Yoshiya Kawamura; Nao Nishida; Taku Miyagawa; Masatoshi Takeda; Tsukasa Sasaki; Katsushi Tokunaga; Norio Ozaki; Hiroshi Ujike; Nakao Iwata
Journal:  Neuropsychopharmacology       Date:  2013-04-12       Impact factor: 7.853

Review 10.  Epigenetic mediation of environmental influences in major psychotic disorders.

Authors:  Bart P F Rutten; Jonathan Mill
Journal:  Schizophr Bull       Date:  2009-09-25       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.